Comparing two drugs for low red blood cells after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests two medicines, luspatercept and epoetin, to see which one helps the body make more red blood cells after a stem cell transplant. If you have low red blood cell counts after your transplant, this trial may help improve your energy and reduce the need for transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a blood cancer (like leukemia or lymphoma).
- You had a stem cell transplant and your red blood cell counts are still low.
- Your cancer is in remission after the transplant.
- You have not taken epoetin before.
- Your natural erythropoietin level is below 500 U/L.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called luspatercept to see if it can help your body make blood cells faster after a stem cell transplant. It is for people with blood cancers and moderate to severe bone marrow scarring (myelofibrosis).
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.
This trial tests whether a medication called luspatercept can help raise red blood cells faster after a stem cell transplant for blood cancer. It aims to reduce severe anemia and improve recovery.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.